[15] Cho JH, Jang HM, Jung HY, et al. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients[J]. Clin Ther, 2018, 40 (1) : 123-134.

[16] Leung HW, Chan A L, Muo C H. Cost-effectiveness of Gemcitabine plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer[J]. Clin Ther, 2016, 38 (5) : 1174-1183.

[17] 管欣, 刘强, 唐文熙, 等. 基于决策树模型对我国 5 种常用非典型抗精神病药一线治疗首发精神分裂症的成本效果分析[J]. 中国新药杂志, 2017, 26 (17) : 2101-2106.

[18] Cotton CC, Erim D, Eluri S, et al. Cost Utility Analysis of Topical Steroids Compared to Dietary Elimination for Treatment of Eosinophilic Esophagitis[J]. Clin Gastroenterol Hepatol, 2017, 15 (6) : 841-849.

[19] 付洁, 吴斌, 林厚文. 伊伐布雷定治疗我国慢性心力衰竭患者的成本-效用分析[J]. 中国药房, 2017, 28 (32) : 4470-4474.

[20] 王海兵, 谷玉娟, 刘小亚. 舒肝解郁胶囊治疗抑郁障碍的成本效用分析[J]. 中国药物经济学, 2017, 12 (9) : 7-12.

[21] Yagudina RI, Kulikov AU, Serpik VG, et al. Concept of Combining Cost-effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making[J]. Value Health Reg Issues, 2017, 13 : 61-66.

[22] Aladul MI, Fitzpatrick RW, Chapman SR. The Effect of New Biosimilars in Rheumatology and Gastroenterology Specialities on UK Healthcare Budgets : Results of a Budget Impact Analysis[J]. Res Social Adm Pharm, 2018, S1551-7411 (17) : -.

[23] Wranik WD, Gambold L, Hanson N, et al. The Evolution of the Cancer Formulary Review in Canada: Can Centralization Improve the Use of Economic Evaluation?[J]. Int J Health Plann Manage, 2017, 32 (2) : e232-e260.

[24] 吴博生, 耿劲松, 黄媛, 等. 药物经济学评价在韩国医保报销决策中的应用[J]. 中国卫生资源, 2014, 17 (4) : 270-273,290.

[25] 周挺, 李洪超, 张籍元, 等. 药物经济学证据在澳大利亚药品福利计划准入中的应用及启示[J]. 中国卫生经济, 2018, 37 (5) : 54-56.

[26] 高胜男, 刘国强. 药物经济学在医药卫生领域的应用[J]. 中国药物经济学, 2017, 12 (8) : 16-18.

(文献来源:中国药物经济学,2019,14(2):122-128)

文章来源：《中国药物经济学》 网址: http://www.zgywjjx.cn/zonghexinwen/2020/0713/374.html